PSDCF is leading the Canebosem Project to research and develop cannabinoid-based medicines for the prevention and management of diabetes. We believe that cannabinoids can play an important role as a cost-effective tool in personalized care plans for patients struggling with diabetes.

Type 2 Diabetes is a metabolic disorder that has become epidemic around the world due to the adoption of sedentary lifestyles, the pervasion of poor diets saturated in carbohydrates, and inadequate patient support for proper care. Critical in the management of diabetes is reducing the heightened risk for serious complications like amputation, blindness, and cancer. To effectively reduce the risk of complications, a patient must control their nutrition, weight, and glycemic levels.

Plant-derived cannabinoids, most of which are not toxic and devoid of psychoactive effects, may represent an effective new strategy in diabetes care. For patients with diabetes, managing their health is a struggle that can result in acute hospitalizations due to hypoglycemia and the development of symptomless long-term complications caused by prolonged poor care.

Project Goals

To improve diabetes care, The Canebosem Project will:

  • Engage in translational cannabinoid research with in-vivo patients to initiate innovation towards further understanding the therapeutic value of cannabinoids in, both, managing diabetes and preventing the onset of long-term complications like cancer, eye disease, and wound healing.
  • Dedicate its resources to better understand the science of cannabinoids and its role in resolving the racial and ethnic health disparities seen in patients with diabetes.
  • Generate evidence-based data on the effectiveness of cannabinoid therapy in various populations with type 2 diabetes, in order to optimize formulas for independent or combination therapies for personalized care plans.

Project Motivation

PSDCF and the Canebosem Project partners believe in the role that cannabinoid therapy plays in lipid signaling and metabolism, the safety of its pharmaceutical application, and its cost-effectiveness for underserved communities. We seek to advance research on relevant medical cannabinoids, and support the development of standardized, effective, and non-psychoactive medicine.

Can cannabinoid treatment play a role in helping patients manage diabetes and its complications? Cannabidiol (CBD), the second leading active compound in cannabis, is already being used in isolation without long-term adverse effect. In Canada, Spain, and the United Kingdom, CBD is approved for prescribed treatment of inflammation and cancer, with successful results. Chronic inflammation has long been known to be involved in the development of insulin resistance, diabetes, and many of its complications.

Can cannabinoids be used for patients with prediabetes to prevent onset of the disease altogether? Early clinical trials are substantiating the role of the body’s endocannabinoid system in the pathogenesis of diabetes. For example, patients receiving a RIO treatment (the antagonist to the CB1 cannabinoid receptor) showed greater weight loss and glycemic control when compared to placebo. The patients had previously been inadequately controlled by either metformin or sulfonylureas.